Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …

The natural history of small-cell lung cancer (SCLC) includes rapid evolution from
chemosensitivity to chemoresistance, although mechanisms underlying this evolution …

Cancer heterogeneity impacts therapeutic response, driving efforts to discover over-arching
rules that supersede variability. Here, we define pan-cancer binary classes based on distinct …

Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …

Metastasis is a major cause of morbidity and mortality in cancer patients. However, the
molecular and cellular mechanisms underlying the ability of cancer cells to metastasize …

Clinical outcomes and treatment modalities for osteosarcoma, the most common primary
cancer of bone, have changed very little over the past 30 years. The peak incidence of …

As one of the most common forms of cancer, lung cancers present as a collection of different
histological subtypes. These subtypes are characterized by distinct sets of driver mutations …

Small cell lung cancer (SCLC) is notorious for its early and frequent metastases, which
contribute to it as a recalcitrant malignancy. To understand the molecular mechanisms …